ES2362886T3 - Derivados de quinolina para el tratamiento de la tuberculosis latente. - Google Patents

Derivados de quinolina para el tratamiento de la tuberculosis latente. Download PDF

Info

Publication number
ES2362886T3
ES2362886T3 ES05815816T ES05815816T ES2362886T3 ES 2362886 T3 ES2362886 T3 ES 2362886T3 ES 05815816 T ES05815816 T ES 05815816T ES 05815816 T ES05815816 T ES 05815816T ES 2362886 T3 ES2362886 T3 ES 2362886T3
Authority
ES
Spain
Prior art keywords
alkyl
phenyl
halogen
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05815816T
Other languages
English (en)
Spanish (es)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2362886T3 publication Critical patent/ES2362886T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES05815816T 2004-12-24 2005-12-08 Derivados de quinolina para el tratamiento de la tuberculosis latente. Expired - Lifetime ES2362886T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP04078529 2004-12-24
EP05105008 2005-06-08

Publications (1)

Publication Number Publication Date
ES2362886T3 true ES2362886T3 (es) 2011-07-14

Family

ID=36736133

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05815816T Expired - Lifetime ES2362886T3 (es) 2004-12-24 2005-12-08 Derivados de quinolina para el tratamiento de la tuberculosis latente.

Country Status (9)

Country Link
JP (5) JP2006182755A (enExample)
KR (2) KR101301573B1 (enExample)
CN (1) CN101087608A (enExample)
BG (1) BG66437B1 (enExample)
EA (1) EA009779B1 (enExample)
ES (1) ES2362886T3 (enExample)
JO (1) JO2695B1 (enExample)
UA (1) UA88766C2 (enExample)
ZA (1) ZA200705160B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
CN103664877A (zh) * 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
CA3016068C (en) * 2016-03-07 2024-02-27 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Also Published As

Publication number Publication date
JP2006182755A (ja) 2006-07-13
JP6426530B2 (ja) 2018-11-21
ZA200705160B (en) 2008-09-25
JP2017141262A (ja) 2017-08-17
BG109180A (bg) 2006-06-30
JP2017141259A (ja) 2017-08-17
CN101087608A (zh) 2007-12-12
EA009779B1 (ru) 2008-04-28
KR20060073416A (ko) 2006-06-28
BG66437B1 (bg) 2014-07-31
JO2695B1 (en) 2013-03-03
KR101301573B1 (ko) 2013-09-04
JP2015157847A (ja) 2015-09-03
EA200500802A1 (ru) 2006-06-30
KR20130041872A (ko) 2013-04-25
JP2013049704A (ja) 2013-03-14
UA88766C2 (ru) 2009-11-25

Similar Documents

Publication Publication Date Title
CA2529265C (en) Quinoline derivatives for the treatment of latent tuberculosis
ES2306146T3 (es) Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos.
ES2395237T3 (es) Derivados de quinolina como compuestos intermedios para inhibidores micobacterianos
TWI580668B (zh) Ｂ型肝炎抗病毒劑
US20230013227A1 (en) Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
BR112019017901A2 (pt) Terapia de combinação
KR20180058829A (ko) Ezh2 억제제로 수모세포종을 치료하는 방법
CN113264939A (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
JP5898061B2 (ja) 細菌のｉｉｉ型分泌系の阻害剤
JP6426530B2 (ja) 潜伏性結核の処置
MXPA05013413A (en) Treatment of latent tuberculosis
HK1114006A (en) Quinoline derivatives for the treatment of latent tuberculosis
HK1186125B (en) Quinoline derivatives for the treatment of latent tuberculosis
CN108926563A (zh) 氰胺染料类药物的新用途